International Journal of Medical Science and Public Health Research https://ijmsphr.com/index.php/ijmsphr <p><strong>International Journal of Medical Science and Public Health Research</strong> (IJMSPHR) is an international, peer-reviewed, open-access journal dedicated to advancing knowledge in medical sciences, public health, clinical research, healthcare management, and allied health disciplines. The journal provides a global platform for researchers, academicians, healthcare professionals, and policymakers to publish high-quality original research, review articles, case studies, and innovative findings. With Crossref DOI assignment, monthly publication, and a rigorous peer-review process, IJMSPHR is committed to promoting scientific excellence, research integrity, and the dissemination of impactful healthcare knowledge worldwide.</p> en-US editor@ijmsphr.com (John Mike) editor@ijmsphr.com (John Mike) Sun, 01 Nov 2026 00:00:00 +0000 OJS 3.3.0.8 http://blogs.law.harvard.edu/tech/rss 60 Evaluation of Platelet and Haemostatic Biomarkers of Methanol Leaves Extract of Chromolaena Odorata In Cyclophosphamide-Induced Thrombocytopenia in Wistar Rats https://ijmsphr.com/index.php/ijmsphr/article/view/329 <p><strong>Thrombocytopenia is a clinically important haematological disorder, but platelet count alone does not describe its effects on platelet biology and haemostasis. This study evaluated the effect of methanol leaf extract of Chromolaena odorata on platelet count, platelet indices (mean platelet volume, MPV; platelet distribution width, PDW; plateletcrit, PCT; platelet large cell ratio, P-LCR), von Willebrand factor (vWF), and fibrinogen in cyclophosphamide-induced thrombocytopenia in Wistar rats. Cyclophosphamide was used solely to induce thrombocytopenia. Acute oral toxicity (LD50) was first determined using Lorke's metho. Twenty-five Wistar rats were allocated to five groups (n=5): normal control, negative control (cyclophosphamide only), and three groups administered cyclophosphamide with the extract orally at 125, 250, or 500 mg/kg respectively for two weeks. Platelet count and indices were measured using an automated haematology analyser, and vWF and fibrinogen were measured by ELISA. Data were analysed by one-way ANOVA (p&lt;0.05). No mortality was observed up to 5000 mg/kg. Significant group differences were observed for platelet count, PDW, PCT, P-LCR, and vWF, but not for MPV or fibrinogen. Cyclophosphamide reduced platelet count, PCT, and vWF and increased PDW and P-LCR. It has been seen that in all the extract-treated groups there is higher platelet count and PCT and lower PDW than the negative control; vWF was highest at 250 mg/kg, and P-LCR was lowest at 125 mg/kg. The extract restored platelet count and returned platelet-turnover indices and vWF toward normal values in cyclophosphamide-induced thrombocytopenic rats. Findings provide experimental evidence that methanol leaves extract of C. odorata possesses promising thrombocytopoietic properties supporting further investigation</strong>.</p> Inoh, I. R., Onuigwe, F. U., Mohamed, K., Raji, A. A., Maniru, N. Copyright (c) 2026 Inoh, I. R., Onuigwe, F. U., Mohamed, K., Raji, A. A., Maniru, N. https://creativecommons.org/licenses/by/4.0 https://ijmsphr.com/index.php/ijmsphr/article/view/329 Fri, 06 Nov 2026 00:00:00 +0000 Hepatitis B And C: Advances in Epidemiology, Diagnosis, Treatment and Prevention, And the Emerging Prospect of Functional Cure — A Narrative Review https://ijmsphr.com/index.php/ijmsphr/article/view/332 <p><strong>Background: Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain leading causes of cirrhosis and hepatocellular carcinoma. WHO estimated that, in 2024, about 240 million people lived with chronic HBV and 47 million with HCV infection, and that these infections caused about 1.3 million deaths.</strong></p> <p><strong>Objective: To synthesise current evidence on the epidemiology, natural history, diagnosis, treatment and prevention of HBV and HCV, and to distinguish established practice from emerging and investigational approaches.</strong></p> <p><strong>Methods: Narrative review of WHO reports, current guidance from WHO, EASL, AASLD–IDSA and CDC, systematic reviews, modelling studies, pivotal trials and regulatory announcements. Searches were run on 9 November 2026 using web search, PubMed records and official websites, with priority given to publications from 2021 to 2026. No patient data were collected.</strong></p> <p><strong>Main findings: The cascade of care remains the central failure. In 2024, 27% of people with chronic HBV knew their status and fewer than 5% were treated, although about half would be eligible under WHO’s 2024 criteria. New HCV infections had fallen by only 8% since 2015. Guidelines now diverge on HBV treatment eligibility. WHO favours simplified criteria for low-resource settings, EASL bases priority mainly on HBV DNA, ALT and fibrosis, and AASLD/IDSA retains phase-based categories. Pangenotypic direct-acting antivirals cure more than 95% of treated HCV infections, but cure confers no immunity and does not remove the cancer risk in established cirrhosis. In 2026, the FDA approved bulevirtide for chronic hepatitis D and bepirovirsen, which produced functional cure in 19%–20% of selected virologically suppressed HBV patients in phase 3 trials. No HCV vaccine exists.</strong></p> <p><strong>Conclusion: Effective prevention and treatment exist for both infections, but elimination remains off track. Progress depends mainly on simplified testing, affordable treatment, timely birth-dose vaccination and harm reduction, with new curative approaches for HBV still limited to selected patients</strong>.</p> Shukurov Bakhtiyar Vakilovich Copyright (c) 2026 Shukurov Bakhtiyar Vakilovich https://creativecommons.org/licenses/by/4.0 https://ijmsphr.com/index.php/ijmsphr/article/view/332 Mon, 09 Nov 2026 00:00:00 +0000 A Comprehensive Assessment Model of Maternal Mortality Among Nigerian Adolescents and Young Adults: Evidence from The Global Burden of Disease Study, 1990–2017 https://ijmsphr.com/index.php/ijmsphr/article/view/328 <p><strong>Maternal mortality among adolescents and young adults remains an important public-health and health-system challenge in Nigeria, where early pregnancy may intersect with inadequate access to skilled obstetric care, socioeconomic disadvantage, and age-related vulnerability. This study develops a comprehensive assessment model for examining maternal mortality among Nigerian adolescents and young adults using the conceptual and analytical foundations of the Global Burden of Disease (GBD) Study, with particular attention to the 1990–2017 period. The study adopts a structured secondary-analysis approach based exclusively on the supplied literature, integrating global mortality evidence with empirical studies from Nigeria and comparable African settings. The proposed assessment model incorporates temporal trends, age-specific mortality, geographical and sociodemographic context, causes of maternal death, and health-system and obstetric factors. Existing evidence indicates that adolescents constitute an important risk group within maternal mortality research, while Nigerian hospital-based studies demonstrate substantial concern regarding obstetric outcomes among teenage pregnancies. The analysis further identifies a gap between broad population-level burden estimation and locally grounded explanations of adolescent maternal mortality. The proposed framework addresses this gap by connecting GBD-derived mortality patterns with contextual evidence concerning obstetric outcomes and health-service conditions. The study concludes that effective assessment of adolescent and young-adult maternal mortality requires simultaneous consideration of age, temporal change, causes of death, and contextual determinants rather than reliance on aggregate maternal mortality measures alone</strong>.</p> Nguyen Minh Anh, Tran Quoc Huy Copyright (c) 2026 Nguyen Minh Anh, Tran Quoc Huy https://creativecommons.org/licenses/by/4.0 https://ijmsphr.com/index.php/ijmsphr/article/view/328 Sun, 01 Nov 2026 00:00:00 +0000